We thus tested the activity of ABT-263, a dual Bcl-2/Bcl-X inhibitor, to restore I-BET762-mediated apoptosis in all resistant B-cell lymphoma cell lines. Here, BCL2 is linked to B-cell non-Hodgkin lymphoma.